Increased risk of atrial fibrillation among patients undergoing coronary artery bypass graft surgery while receiving nitrates and antiplatelet agents

Jimmy T. Efird¹, Charulata Jindal¹, Andy C. Kiser², Shahab A. Akhter², Patricia B. Crane³, Alan P. Kypson⁴, Aaron L. Sverdlov⁵, Stephen W. Davies⁶, Linda C. Kindell² and Ethan J. Anderson⁷

Abstract

Background: Postoperative atrial fibrillation (POAF) is a frequent complication of coronary artery bypass graft (CABG) surgery. This arrhythmia occurs more frequently among patients who receive perioperative inotropic therapy (PINOT). Administration of nitrates with antiplatelet agents reduces the conversion rate of cyclic guanosine monophosphate to guanosine monophosphate. This process is associated with increased concentrations of free radicals, catecholamines, and blood plasma volume. We hypothesized that patients undergoing CABG surgery who receive PINOT may be more susceptible to POAF when nitrates are administered with antiplatelet agents.
Methods: Clinical records were examined from a prospectively maintained cohort of 4,124 patients undergoing primary isolated CABG surgery to identify POAF-associated factors.

Results: POAF risk was increased among patients receiving PINOT, and the greatest effect was observed when nitrates were administered with antiplatelet therapy. Adjustment for comorbidities did not substantively change the study results.

Conclusions: Administration of nitrates with certain antiplatelet agents was associated with an increased POAF risk among patients undergoing CABG surgery. Additional studies are needed to determine whether preventive strategies such as administration of antioxidants will reduce this risk.

Keywords
Antiplatelet agents, coronary artery bypass graft, inotropes, nitric oxide, nitrate tolerance, postoperative atrial fibrillation

Date received: 25 August 2017; accepted: 9 April 2018

Introduction
Postoperative atrial fibrillation (POAF) is a significant predictor of stroke, future arrhythmias, heart failure, and mortality among patients undergoing coronary artery bypass graft (CABG) surgery.\(^1,2\) Nitrates and inotropes are important drugs commonly used to manage cardiorenal function. Both have potent effects on the heart by increasing cyclic purine nucleoside production.\(^3,4\) Inotropes improve cardiac output by their inotropic action (i.e., increasing intracellular calcium), while nitrates/nitroglycerin reduce oxygen demand in the myocardium through a reduction in preload and a weak negative inotropic effect.\(^4,5\) In contrast to inotropic therapy, which increases the risk of POAF, the administration of nitrates have been shown to be protective against POAF.\(^6–8\) Furthermore, the combined use of nitrates with antiplatelet agents is known to reduce the conversion rate of cyclic guanosine monophosphate (cGMP) to guanosine monophosphate (GMP), which may lead to increased concentrations of free radicals and catecholamines, an increased blood plasma volume, and a higher POAF risk.\(^9,10\) The present study was performed to test the following hypothesis: that patients undergoing CABG surgery who receive perioperative inotropic therapy (PINOT) may be at increased risk for POAF when nitrates are administered with antiplatelet agents.

Methods
Setting and data collection
This study was conducted at the East Carolina Heart Institute (ECHI), which provides comprehensive cardiovascular care to patients predominantly from the eastern region of North Carolina, a rural area covering 29 counties. Most patients receiving care live and remain within a 150-mile radius of the Institute.

Clinical information was prospectively entered into the Society of Thoracic Surgeons Adult Cardiac Surgery Database at the ECHI as previously described and summarized below.\(^11\) Patients aged
<60 years and undergoing primary isolated CABG surgery from 1992 to 2007 were included in this analysis. Perioperative inotropic information, which was collected as part of a quality assurance initiative, was not available in our database after 2007.

Comorbidities, demographic data, preoperative medications, and surgical details were obtained at the time of surgery. Patients with a history of preoperative paroxysmal, persistent, or permanent AF/atrial flutter and the use of preoperative inotropic agents were excluded from the study (approximately 2% of patients). The study and a waiver of participant consent were approved by the Institutional Review Board at the Brody School of Medicine, East Carolina University (UMCIRB 12-002107).

**Definitions**

POAF and comorbidities, such as diabetes mellitus, hypertension, left main coronary artery disease, peripheral artery disease, prior myocardial infarction, three-vessel coronary disease, and unstable heart failure, were defined according to the standard Society of Thoracic Surgeons criteria. We evaluated hospital notes, medication reports, outpatient medical records, physicians’ documentation, and radiology readings to document the presence of these comorbidities. The cardiac rhythm was continuously monitored by electrocardiography until the patients were discharged from the hospital.

PINOT included the administration of sympathomimetics (dobutamine, dopamine, epinephrine, isoprenaline, and nor-epinephrine) and phosphodiesterase-3 inhibitors (amrinone and milrinone). Each class boosts cardiac output and renal perfusion by increasing myocardial contractility, vasodilation, or both. Sympathomimetics increase cardiac contractility by facilitating calcium influx into cardiac myocytes through cyclic adenosine monophosphate-mediated mechanisms. Similarly, phosphodiesterase-3 inhibitors increase intracellular cyclic adenosine monophosphate (by decreasing cyclic adenosine monophosphate degradation) and calcium influx, while additionally increasing cGMP in the vasculature. They also selectively lower the left ventricular end-diastolic pressure and the B-type natriuretic peptide concentration.

Antiplatelet agents were defined as inhibitors of adenosine diphosphate (e.g., clopidogrel), glycoprotein IIb/IIIa (e.g., abciximab, epifibatide, and tirofiban), or phosphodiesterase (e.g., dipyridamole). Except for combination antiplatelet formulations such as extended-release Aggrenox®, aspirin was placed into a separate category because of its different mechanism of antiplatelet activity through the cyclooxygenase pathway.

Organic nitrates, in the form of nitroglycerine, were administered by intravenous injection within 24 hours preceding surgery, mainly to patients with prior routine use of nitrates.

**Statistical analysis**

Categorical variables are reported as frequencies and percentages, whereas continuous variables are reported as medians and interquartile ranges. Statistical significance for categorical variables was determined using Fisher’s exact test and the Deuchler–Wilcoxon procedure for continuous variables. An iterative expectation–maximization algorithm was used to account for missing values.

Log-binomial regression was used to estimate the relative risks (RRs) and 95% confidence intervals (CIs) for POAF. Goodness-of-fit was assessed using Akaike’s information criterion and leverage/casewise diagnostic statistics, generalized to log-binomial regression. All models
satisfied convergence and admissibility criteria (i.e., linear predictor constrained to be negative). The nitrates/inotrope category (+/−), believed to represent the lowest risk for POAF, was designated as the reference group for this variable in our log-binomial models.

Multivariable models included variables that have been associated with POAF in prior reports, regardless of their statistical significance in the current analysis.18,19 These included patient age, diabetes mellitus, hypertension, peripheral arterial disease, race, sex, three-vessel coronary disease, and unstable heart failure. Other demographic variables, prior medical history, and preoperative medicines were entered into the model in a post hoc pairwise manner. Cardiac function variables were not included in the multivariable analyses because of their potential to be a factor in the causal pathway from exposure to outcome (or a descending proxy for such a factor).20 P-values for point estimates were computed assuming asymptotic normality. A likelihood ratio test for risk differences between strata was used to identify statistically significant interaction effects.

The method established by Holly et al.21 was used for rounding. Analyses were performed using SAS Version 9.4. (SAS Institute, Cary, NC, USA).

**Results**

In total, 4,124 patients were included in this study (median age, 53 years; interquartile range, 8 years; 70% male) (Table 1). Hypertension (66%) was the most common comorbidity, followed by diabetes mellitus (31%). Approximately 61% of patients had three-vessel coronary revascularization with a median postoperative length of stay of 5 days. Three-vessel coronary disease was present in 65% of patients with POAF, compared with 6% and 29% for one- and two-vessel coronary disease, respectively (P=0.0048).

Preoperative nitrates were used by 17% of patients. Catecholamines were the predominant drug class used for PINOT, with 34% of patients receiving these compounds (Table 2). Only 3% of patients received phosphodiesterase-3 inhibitors. The use of PINOT was associated with a 56% increased RR for POAF (P<0.0001).

In the presence of antiplatelet agents, the use of preoperative nitrates increased the POAF RR difference associated with PINOT (+/−: RR=2.9, 95%CI=1.6–5.1 vs. −/+: RR=2.0, 95%CI=1.2–3.4), in contrast to the absence of antiplatelet agents (+/+: RR=0.90, 95%CI=0.46–1.8 vs. −/+: RR=1.6, 95%CI=0.98–2.5). This opposite effect is illustrated by the vertical arrows in Table 3 (Pinteraction=0.0069). Multivariable adjustment for age, diabetes mellitus, hypertension, peripheral arterial disease, race, sex, three-vessel coronary disease, and unstable heart failure did not substantively change the results (Pinteraction=0.011). Similarly, the post hoc pairwise inclusion of other demographic variables, prior medical history, and preoperative medicines from Table 1 into the multivariable models did not affect the findings. The exclusion of phosphodiesterase-3 inhibitors and the adjustment for the time period of surgery (before the year 2000 vs. 2000 and later) also had little effect on the analyses.

**Discussion**

AF is a common postoperative complication following CABG surgery and is associated with increased mortality, morbidity, hospital costs, and readmission rates.2,22 The use of PINOT is an established risk factor for POAF.23 Identifying preoperative factors associated with this risk is an important area of concern.
Table 1. Patient characteristics (N=4124)*.

| Patient characteristics† | Inotrope‡ | No inotrope‡ | P§ | Inotrope‡ | No inotrope‡ | P§ |
|--------------------------|----------|-------------|----|----------|-------------|----|
|                         | Nitrate n (%) or Q2 [IQR] | No nitrate n (%) or Q2 [IQR] |    | Nitrate n (%) or Q2 [IQR] | No nitrate n (%) or Q2 [IQR] |    |
| Overall                  | 300 (21) | 1122 (79)   |    | 391 (14) | 2311 (86)   |    |
| Demographics             |          |             |    |          |             |    |
| Age                      | 54 [8]   | 54 [8]      | 0.57| 52 [9]   | 53 [8]      | 0.072|
| Black                    | 63 (21)  | 260 (23)    | 0.44| 59 (50)  | 399 (17)    | 0.31 |
| Male                     | 196 (65) | 799 (71)    | 0.055| 300 (77) | 1828 (79)   | 0.29 |
| Obesity (BMI ≥ 30 kg/m²) | 156 (52) | 591 (53)    | 0.85| 155 (40) | 1058 (46)   | 0.024|
| Prior Medical History    |          |             |    |          |             |    |
| Diabetes                 | 112 (37) | 453 (40)    | 0.35| 95 (24)  | 629 (27)    | 0.24 |
| Dialysis                 | 14 (5)   | 28 (3)      | 0.55| 0 (0)    | 36 (2)      | 0.0068|
| Elective CABG surgery    | 23 (8)   | 487 (44)    | <0.0001| 38 (10) | 1201 (52)   | <0.0001|
| Hypertension             | 10 (70)  | 798 (71)    | 0.72| 239 (61) | 1476 (64)   | 0.31 |
| LMCA disease             | 72 (24)  | 225 (20)    | 0.15| 68 (17)  | 382 (17)    | 0.66 |
| LVEF (%)                 | 45 [23]  | 50 [25]     | 0.011| 50 [15]  | 55 [15]     | <0.0001|
| Peripheral artery disease| 30 (10)  | 129 (12)    | 0.54| 23 (6)   | 152 (7)     | 0.66 |
| Prior myocardal infarction| 173 (58)| 471 (42)    | <0.0001| 200 (51) | 720 (31)    | <0.0001|
| Recent smoker            | 109 (36) | 373 (33)    | 0.34| 191 (49) | 850 (37)    | <0.0001|
| Three-vessel coronary disease | 217 (72)| 799 (71)    | 0.72| 209 (53) | 1287 (56)   | 0.41 |
| Unstable heart failure   | 38 (13)  | 191 (17)    | 0.077| 21 (5)   | 147 (6)     | 0.50 |
| Preoperative medications |          |             |    |          |             |    |
| ACEIs/ARBs               | 79 (26)  | 375 (33)    | 0.021| 93 (24)  | 529 (23)    | 0.70 |
| Anticoagulants           | 215 (72) | 252 (22)    | <0.0001| 302 (77) | 479 (21)    | <0.0001|
| Antiplatelet agents      | 188 (63) | 603 (54)    | 0.0060| 231 (59) | 1312 (57)   | 0.41 |
| Aspirin                  | 193 (64) | 755 (67)    | 0.34| 261 (67) | 1603 (69)   | 0.32 |
| Beta blockers            | 182 (61) | 633 (56)    | 0.19| 223 (57) | 1228 (53)   | 0.15 |
| Calcium channel blockers | 69 (23)  | 340 (30)    | 0.015| 78 (20)  | 737 (32)    | <0.0001|
| Digoxin                  | 14 (5)   | 65 (6)      | 0.57| 7 (2)    | 57 (2)      | 0.59 |
| Diuretics                | 50 (17)  | 265 (24)    | 0.0098| 42 (11)  | 281 (12)    | 0.45 |
| Lipid-lowering agents    | 94 (31)  | 461 (41)    | 0.0022| 108 (28) | 840 (36)    | 0.0009|
| Perioperative variables  |          |             |    |          |             |    |
| Cardiopulmonary bypass   | 292 (97) | 1090 (97)   | 1.0 | 366 (94) | 217 (87)    | 0.0002|
| Colloid cardioplegia     | 219 (73) | 918 (82)    | 0.0011| 322 (82) | 2020 (87)   | 0.0079|
| Crystalloid cardioplegia | 236 (79) | 857 (76)    | 0.44| 287 (73) | 1705 (74)   | 0.90 |
| Crystalloid+O₂ cardioplegia | 143 (78)| 495 (44)    | 0.30| 197 (50) | 1200 (52)   | 0.58 |
| Cross-clamp time (min)   | 61 [29]  | 63 [30]     | 0.76| 57 [29]  | 56 [26]     | 0.45 |
| Hospital LOS (days)      | 5 [3]    | 5 [2]       | 0.25| 4 [1]    | 4 [1]       | 0.27 |
| Intra-aortic balloon pump| 194 (65) | 1023 (91)   | <0.0001| 327 (84) | 2246 (97)   | <0.0001|
| Perfusion time (min)     | 100 [41]| 101 [47]    | 0.91| 100 [41]| 101 [47]    | 0.55 |
| Total ICU time (hours)   | 28 [28]  | 25 [26]     | 0.13| 22 [7]   | 22 [8]      | 0.23 |

*Isolated primary CABG, 1992–2007. †Comparison group was the complement. ‡Perioperative inotropes. §P-values were computed using Fisher's exact or Deuchler–Wilcoxon tests. ††Excludes patients with poor condition of the aorta, left ventricular weakness, and other contraindicated conditions (<0.5%). #Pre-/intraoperative balloon pump placement only. ACEIs=angiotensin-converting enzyme inhibitors; ARBs=angiotensin receptor blockers; BMI=body mass index; CABG=coronary artery bypass graft; ICU=intensive care unit; IQR=interquartile range; LMCA=left main coronary artery; LOS=length of stay; LVEF=left ventricular ejection fraction; O₂=oxygen; Q₂=median
Interaction of nitrates with antiplatelet drugs

Since the late 19th century, when it was first observed that amyl nitrate alleviated chest pain, organic nitrates have been routinely prescribed as cardioprotective, anti-ischemic agents to treat angina, acute myocardial infarction, heart failure, pulmonary edema, and severe arterial hypertension. These compounds, by releasing nitric oxide (NO), facilitate left ventricular function, vasodilation by venous pooling, and preload reduction. In hypoxic conditions, nitrate therapy results in a redistribution of blood from the central circulation into larger-capacitance veins, thus reducing the ventricular filling pressure and wall tension and decreasing myocardial oxygen consumption. 

Table 2. Inotropic support and nitrate use by postoperative cardiac rhythm (N=4124) *

| Inotropic agent       | Sinus rhythm† | POAF†          |
|-----------------------|---------------|----------------|
|                       | Nitraten (%)  | No Nitrate n (%) | P‡ | Nitraten (%)  | No nitrate n (%) | P‡ |
| Overall               | 81 (16)       | 412 (84)       | —  | 610 (17)     | 3021 (83)        | —  |
| Sympathomimetics      |               |                |    |              |                |    |
| Dobutamine            | 4 (5)         | 19 (5)         | 0.78 | 14 (2)     | 37 (1)          | 0.056 |
| Dopamine              | 43 (53)       | 150 (36)       | 0.0061 | 231 (38) | 865 (29)        | <0.0001 |
| Epinephrine           | 8 (10)        | 31 (8)         | 0.50 | 44 (7)     | 113 (4)         | 0.0003 |
| Isoprenaline          | 0 (0)         | 1 (<1)         | 1.0 | 1 (<1)     | 10 (<1)         | 0.70 |
| Norepinephrine        | 10 (12)       | 18 (4)         | 0.014 | 24 (4)     | 66 (2)          | 0.015 |
| Total                 | 46 (57)       | 173 (42)       | 0.020 | 250 (41)   | 927 (31)        | <0.0001 |
| Phosphodiesterase-3 inhibitors |     |                |    |              |                |    |
| Amrinone              | 4 (5)         | 6 (1)          | 0.065 | 13 (2)     | 25 (1)          | 0.0077 |
| Milrinone             | 5 (6)         | 10 (2)         | 0.082 | 13 (2)     | 36 (1)          | 0.081 |
| Total                 | 9 (11)        | 14 (3)         | 0.0065 | 26 (4)     | 61 (2)          | 0.0020 |

1 Isolated primary coronary artery bypass graft procedures from 1992–2007. † Column percentages may add up to more than 100% because some patients received more than one inotrope. ‡P-value computed using Fisher’s exact test.

Table 3. Relative risk for postoperative atrial fibrillation by preoperative medications (N=4124) *

| Nitrates/| Antiplatelet agents (n=2334) | No antiplatelet agents (n=1790) |
|---------|------------------------------|---------------------------------|
| inotropes n (%) | Univariable RR (95%CI)† | Multivariable‡ RR (95%CI)† | n (%) | Univariable RR (95%CI)‡ | Multivariable‡ RR (95%CI)‡ |
| +/−       | 231 (10) | 1.0 (Ref) | 1.0 (Ref) | 160 (9) | 1.0 (Ref) | 1.0 (Ref) |
| +/+       | 188 (8)  | 2.9 (1.6–5.1) | 2.6 (1.5–4.7) | 112 (6) | 0.90 (0.46–1.8) | 0.88 (0.44–1.7) |
| −/+       | 603 (26) | 2.0 (1.2–3.4) | 1.8 (1.1–3.1) | 519 (29) | 1.6 (0.98–2.5) | 1.4 (0.86–2.1) |
| −/−       | 1312 (56) | 1.5 (0.92–2.6) | 1.5 (0.87–2.4) | 999 (56) | 0.89 (0.56–1.4) | 0.88 (0.56–1.4) |

1 Isolated primary coronary artery bypass graft procedures from 1992–2007. || RR and 95% CI were computed using maximum likelihood log-binomial regression. ‡ Adjusted for age, diabetes, hypertension, peripheral arterial disease, race, sex, three-vessel coronary disease, and unstable heart failure. Arrows indicate direction of the interaction effect. Likelihood ratio test for interaction, P_univariable = 0.0069, and P_multivariable = 0.011. CI = confidence interval; RR = relative risk; Ref = reference.

Interaction of nitrates with antiplatelet drugs

Since the late 19th century, when it was first observed that amyl nitrate alleviated chest pain, organic nitrates have been routinely prescribed as cardioprotective, anti-ischemic agents to treat angina, acute myocardial infarction, heart failure, pulmonary edema, and severe arterial hypertension.
between oxygen demand and supply in ischemic regions of the heart and vasculature, nitrates further help to reduce the magnitude, frequency, and velocity of reflected waves in the arterial circulation.26

Nitrates are an exogenous source of NO, which is a gaseous free radical and cellular messenger that facilitates myocardial relaxation and dilation of the coronary arteries, systemic veins, and arterioles.27 Conversely, reduced bioavailability of NO is associated with endothelial dysfunction, arterial stiffness, and hypertension. Even in the presence of endothelial dysfunction, organic nitrates are able to produce an endothelial-dependent relaxation factor (i.e., NO).28

By way of their conversion to NO, nitrates are believed to play an important role in stabilizing cardiac output, preventing post-infarction ventricular remodeling, and reducing myocardial infarction-related mortality.25,29,30 Other properties include enhanced antioxidant effects, production of cytoprotective prostanoids, and stimulation of sacrolemmal and mitochondrial KATP channels.31 In contrast, they inhibit proapoptotic proteins, beta-adrenergic stimulation, and influx through L-type calcium channels. Although NO has a relatively short half-life, the above-mentioned processes may represent upstream factors that underlie longer-time ischemic postconditioning, including the delayed cardioprotective actions of phosphodiesterase-5 inhibitors, stabilization of tissue pH, decreased generation of reactive oxygen species, cardiac tissue remodeling, and prevention of hypercontraction.31,32

Therapeutic doses of antiplatelet agents together with NO are believed to increase cGMP levels, desensitize NO/cGMP-mediated vasodilation, and supersensitize calcium-mediated vasoconstriction.9 Additionally, nitrates are believed to have nonselective antiplatelet activity making them capable of inhibiting platelet aggregation in response to inotropes.27,33

NO increases soluble guanylate cyclase and cGMP, which inversely affects platelet aggregation.34 This is accompanied by the inhibition of agonist-mediated calcium flux and the reduction of fibrinogen binding to the glycoprotein IIb/IIIa receptor. The disruption of fibrinogen binding represents an important mechanism by which platelets are impaired, with nitrates believed to play a mediating role in this process. However, the synergistic effect between nitrates and antiplatelet agents is complicated, both causing and preventing thrombolytic events in patients.35

**Interpretation of findings**

We observed no interaction between nitrates and other preoperative medications in the dataset, suggesting that nitrates and antiplatelet agents may uniquely affect the risk of POAF. Several potential mechanisms may underlie this result, including oxidative stress (free radicals), catecholamines, neurohormonal activation, sulfhydryl group donation, and plasma volume expansion36 (Figure 1).10,37–40 Additionally, various metabolic and genetic factors regulating the production, degradation, and conversion of these compounds in cardiovascular tissue may have contributed to this effect.36 However, explaining the exact mechanism for this interaction, if biologic in nature, was beyond the scope of the present research.

**Strengths and limitations**

The current analysis was strengthened by its large sample size, few missing values, and systematic collection of exposure and outcome data using standard Society of Thoracic Surgeons definitions. Additionally, our institution implemented special database fields to record information on PINOT use, which is not available.
However, a few limitations should be noted when considering our results. NO bioavailability is well known to be affected by polymorphisms (rs2070744 and rs1799983) in the endothelial NO synthase gene, including variable numbers of tandem repeats in intron 4.\textsuperscript{41–43} Similarly, genetic variants in the cytochrome P450 2C19 gene play an important role in determining if the antiplatelet drug clopidogrel is converted to an active metabolite with antiplatelet activity.\textsuperscript{44} These reduced-function polymorphisms, which vary among individuals and populations, may have confounded our findings.\textsuperscript{45,46} However, the patients in this study were not genotyped; therefore, we were unable to include these factors in the analyses. Additionally, no information was collected on the dose and duration of inotrope/nitrate use, antiplatelet use, and other factors potentially affecting the risk of POAF (e.g., diet, inflammation, oxidative stress, and atrial size/dimension).\textsuperscript{8,47}

Heart failure is both a frequent indication for PINOT and a significant risk factor for POAF, and the possibility remains that preoperative nitrate and antiplatelet use may simply reflect treatment of underlying symptoms rather than directly affect the risk of POAF. To minimize this effect (and other potential sources of intermediate causal confounding by indication), we restricted our analysis to patients aged <60 years, and various outcome-related covariates were included in the multivariable models.\textsuperscript{48} Heart failure is an indication for nitrate and inotrope use.\textsuperscript{49,50} While we could have excluded patients with heart

---

**Figure 1.** Potential pathways underlying the interaction of nitrates and antiplatelet agents and the risk of POAF

Nitrates are an exogenous source of NO that, under normal conditions, are cardioprotective (by increasing the concentration of cGMP). The use of nitrates in combination with antiplatelet drugs may increase the concentrations of free radicals and catecholamines and the blood plasma volume, which are potential factors contributing to the development of POAF. cGMP=cyclic guanosine monophosphate; GMP=guanosine monophosphate; NO=nitric oxide; PDE=phosphodiesterase; POAF=postoperative atrial fibrillation; sGC=soluble guanylate cyclase.
failure instead of limiting our analyses by age, this would have prevented examination of the interaction of nitrates/inotropes with antiplatelet agents. Residual selection bias remains a possible explanation of our results; however, this would be an unlikely chance event given the opposite linear RR effects for antiplatelets (yes vs. no) observed in Table 3.

Biological samples were not collected in this study. Consequently, we were unable to directly access the uptake of nitrates into vascular smooth muscles and other factors indicative of pharmacologic tolerance (e.g., decreases in intracellular sulfhydryl groups and cGMP formation, inhibition of guanylate cyclase, stimulation of specific phosphodiesterases, and reduced vasodilation). These techniques may prove to be useful in future studies.

Furthermore, we did not use electron paramagnetic resonance spectroscopy to directly detect NO or perform a proteomic analysis to measure endogenous S-nitrosylation. These techniques may prove to be useful in future studies.

**Future directions**

Vitamin C, which has been shown to decrease the incidence of POAF and peroxynitrite formation following atrial pacing, offers one approach toward disrupting the putative interaction between nitrates and antiplatelet agents. Another approach is the intermittent use of nitrates (i.e., “nitrate holiday”). However, this strategy has been viewed with caution because of the potential rebound risk and consequent outcomes (e.g., myocardial infarction and death). The use of sulfhydryl donor therapy (e.g., acetylcholine, methionine, and captopril) has similarly been associated with undesirable adverse events.

**Summary**

We observed a hitherto unreported increased risk of POAF associated with the interaction between nitrates and antiplatelet agents among patients undergoing CABG surgery who received PINOT. While the mechanisms underlying this effect are complex, our findings may have practical clinical implications. For example, if the outcomes observed in the current study are indicative of a true pharmacologic interaction, then targeted interventions involving anti-inflammatory agents may potentially be a safe and low-cost option for reducing the risk of POAF. Conversely, the reported interaction between nitrates and antiplatelet therapy may merely reflect a patient’s clinical status or the underlying acuity of CABG surgery. Nonetheless, we have identified a set of patients, based on their nitrate and antiplatelet status, who may be at higher risk of POAF. The careful postoperative monitoring of this risk group remains a prudent strategy.

**Authors’ contributions**

J.T.E. and C.J. conceived the manuscript and wrote the first draft. A.C.K., S.A.A., P.B.C., A.P.K., A.S., S.W.D., L.C.K., and E.J.A. provided critical feedback and contributed to the final draft of the manuscript. J.T.E. analyzed the data. L.C.K. supervised the data management and validation of the final dataset. All authors approved the final version of the manuscript.

**Acknowledgements**

The authors thank the East Carolina Heart Institute and ECU College of Nursing for providing the resources to conduct this study. The authors also acknowledge the following individuals for their valuable advice and assistance: W. Randolph Chitwood, MD; Amar Patel; Samantha Gonzalez; Peter MacIsaac, MBBS, FRACGP; and Ola Hammarsten, MD, PhD.

**Declaration of conflicting interest**

The authors declare that there is no conflict of interest.
Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by the National Institutes of Health grant R01HL122863 (J.T.E., E.J.A.). A.L.S. is supported by the Heart Foundation of Australia Future Leader Fellowship (Award ID 101918).

References
1. Hart RG and Halperin JL Atrial fibrillation and stroke: concepts and controversies. Stroke 2001; 32: 803–808.
2. Benjamin EJ, Wolf PA, D’Agostino RB, et al. Impact of atrial fibrillation on the risk of death the Framingham Heart Study. Circulation 1998; 98: 946–952.
3. Ignarro LJ. Endothelium-derived nitric oxide: pharmacology and relationship to the actions of organic nitrate esters. Pharm Res 1989; 6: 651–659.
4. Mayhew DJ and Palmer K. Inotopes. Anaesth Intensive Care 2015; 16: 508–512.
5. Friebe A and Koesling D. Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res 2003; 93: 96–105.
6. Palmer K and Pennefather SH. Inotropes. Anaesth Intensive Care 2009; 10: 362–366.
7. Bolesta S, Aungst TD and Kong F. Effect of sodium nitroprusside on the occurrence of atrial fibrillation after cardiothoracic surgery. Ann Pharmacother 2012; 46: 785–792.
8. Morin DP, Bernard ML, Madias C, et al. The State of the Art: Atrial Fibrillation Epidemiology, Prevention, and Treatment. Mayo Clin Proc 2016; 91: 1778–1810.
9. Kim D, Rybalkin SD, Pi X, et al. Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation 2001; 104: 2338–2343.
10. Munzel T, Daiber A and Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ Res 2005; 97: 618–628.
11. Efird JT, O’Neal WT, Griffin WF, et al. Increased coronary artery disease severity in black women undergoing coronary bypass surgery. Medicine (Baltimore) 2015; 94: e552.
12. Stamm C, Friehs I, Cowan DB, et al. Dopamine treatment of postschematic contractile dysfunction rapidly induces calcium-dependent pro-apoptotic signaling. Circulation 2002; 106 (12 Suppl 1): 1290–1298.
13. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325: 1468–1475.
14. Kawamura A, Yoshikawa T, Takahashi T, et al. Randomized trial of phosphodiesterase inhibitors versus catecholamines in patients with acutely decompensated heart failure. Jpn Circ J 2001; 65: 858–862.
15. Fleming GA, Murray KT, Yu C, et al. Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery. Circulation 2008; 118: 1619–1625.
16. Scharf RE. Drugs that affect platelet function. Semin Thromb Hemost 2012; 38: 865–883.
17. Marschner IC and Gillett AC. Relative risk regression: reliable and flexible methods for log-binomial models. Biostatistics 2012; 13: 179–192.
18. Mathew JP, Fontes ML, Tudor IC, et al. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004; 291: 1720–1729.
19. Tran DT, Perry JJ, Dupuis JY, et al. Predicting New-Onset Postoperative Atrial Fibrillation in Cardiac Surgery Patients. J Cardiothorac Vasc Anesth 2015; 29: 1117–1126.
20. Schisterman EF, Cole SR and Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology 2009; 20: 488.
21. Holly EA, Whittemore AS, Aston DA, et al. Anal cancer incidence: genital warts, anal fissure or fistula, hemorrhoids, and smoking. J Natl Cancer Inst 1989; 81: 1726–1731.
22. LaPar DJ, Speir AM, Crosby IK, et al. Postoperative atrial fibrillation significantly increases mortality, hospital readmission, and hospital costs. Ann Thorac Surg 2014; 98: 527–533; discussion 533.
23. Hashemzadeh K, Dehdilani M and Dehdilani M. Postoperative Atrial Fibrillation following Open Cardiac Surgery: Predisposing Factors and Complications. *J Cardiovasc Thorac Res* 2013; 5: 101–107.

24. Marsh N and Marsh A. A short history of nitroglycerine and nitric oxide in pharmacology and physiology. *Clin Exp Pharmacol Physiol* 2000; 27: 313–319.

25. Smith ER, Smiseth OA, Kingma I, et al. Mechanism of action of nitrates. Role of changes in venous capacitance and in the left ventricular diastolic pressure-volume relation. *Am J Med* 1984; 76: 14–21.

26. Abrams J. The role of nitrates in coronary heart disease. *Arch Intern Med* 1995; 155: 357–364.

27. McIntyre M and Dominiczak AF. Nitric oxide and cardiovascular disease. *Postgrad Med J* 1997; 73: 630–634.

28. Omar SA, Artime E and Webb AJ. A comparison of organic and inorganic nitrates/nitrites. *Nitric Oxide* 2012; 26: 229–240.

29. Held P. Effects of nitrates on mortality in acute myocardial infarction and in heart failure. *Br J Clin Pharmacol* 1992; 34 Suppl 1, 25S–28S.

30. Sutton MGSJ and Sharpe N. Left ventricular remodeling after myocardial infarction pathophysiology and therapy. *Circulation* 2000; 101: 2981–2988.

31. Jones SP and Bolli R. The ubiquitous role of nitric oxide in cardioprotection. *J Mol Cell Cardiol* 2006; 40: 16–23.

32. Vinten-Johansen J and Shi W. Perconditioning and postconditioning: current knowledge, knowledge gaps, barriers to adoption, and future directions. *J Cardiovasc Pharmacol Ther* 2011; 16: 260–266.

33. Zhou RH and Frishman WH. The antiplatelet effects of nitrates: is it of clinical significance in patients with cardiovascular disease? *Cardiol Rev* 2010; 18: 198–203.

34. Weber AA, Strobach H and Schror K. Direct inhibition of platelet function by organic nitrates via nitric oxide formation. *Eur J Pharmacol* 1993; 247: 29–37.

35. Lee DH, Kim MH, Guo LZ, et al. Concomitant nitrates enhance clopidogrel response during dual anti-platelet therapy. *Int J Cardiol* 2016; 203: 877–881.

36. Rutherford JD. Nitrate tolerance in angina therapy. How to avoid it. *Drugs* 1995; 49: 196–199.

37. Oral H. Post-operative atrial fibrillation and oxidative stress: a novel causal mechanism or another biochemical epiphenomenon? *J Am Coll Cardiol* 2008; 51: 75–76.

38. Parker JO and Parker JD. Neurohormonal activation during nitrate therapy: a possible mechanism for tolerance. *Am J Cardiol* 1992; 70: 93B–97B.

39. Kaplan JA, Reich DL and Savino JS. Kaplan’s Cardiac Anesthesia: Expert Consult Premium. Saunders: Elsevier, 2011, pp. 933–948.

40. Anderson EJ, Efird JT, Kiser AC, et al. Plasma Catecholamine Levels on the Morning of Surgery Predict Post-Operative Atrial Fibrillation. *JACC Clin Electrophysiol* 2017; 3: 1456–1465.

41. Casas JP, Cavalleri GL, Bautista LE, et al. Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review. *Am J Epidemiol* 2006; 164: 921–935.

42. Rabelink TJ and Luscher TF. Endothelial nitric oxide synthase: host defense enzyme of the endothelium? *Arterioscler Thromb Vasc Biol* 2006; 26: 267–271.

43. Luscher TF and Noll G. Is it all in the genes…? Nitric oxide synthase and coronary vasospasm. *Circulation* 1999; 99: 2855–2857.

44. Miao J, Liu R and Li Z. Cytochrome P-450 polymorphisms and response to clopidogrel. *N Engl J Med* 2009; 360: 2250–2251.

45. Xie HG, Kim RB, Wood AJ, et al. Molecular basis of ethnic differences in drug disposition and response. *Annu Rev Pharmacol Toxicol* 2001; 41: 815–850.

46. Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. *Pharmacogenetics* 1997; 7: 59–64.
physiologic context for potential health benefits. *Am J Clin Nutr* 2009; 90: 1–10.

48. Sverdlov AL, Ngo DTM, Chan WPA, et al. Aging of the Nitric Oxide System: Are We as Old as Our NO? *J Am Heart Assoc* 2014; 3: e000973.

49. Nossaman VE, Nossaman BD and Kadowitz PJ. Nitrates and nitrites in the treatment of ischemic cardiac disease. *Cardiology in review* 2010; 18: 190–197.

50. Toma M and Starling RC. Inotropic therapy for end-stage heart failure patients. *Curr Treat Options Cardiovasc Med* 2010; 12: 409–419.

51. Parker JO. Nitrate tolerance. *Am J Cardiol* 1985; 56: 28i–31i.

52. Bertel O. Nitrate tolerance. *Schweiz Med Wochenschr* 1988; 118: 1892–1898.

53. Jaffrey SR, Erdjument-Bromage H, Ferris CD, et al. Protein S-nitrosylation: a physiological signal for neuronal nitric oxide. *Nat Cell Biol* 2001; 3: 193–197.

54. Hogg, N. Detection of nitric oxide by electron paramagnetic resonance spectroscopy. *Free Radic Biol Med*. 2010; 49: 122–129.

55. d’Uscio LV, Milstien SRichardson D, et al. Long-term vitamin C treatment increases vascular tetrahydrobiopterin levels and nitric oxide synthase activity. *Circ Res* 2003; 92: 88–95.

56. Baker WL and Coleman CI. Meta-analysis of ascorbic acid for prevention of postoperative atrial fibrillation after cardiac surgery. *Am J Health Syst Pharm* 2016; 73: 2056–2066.

57. Hemila H and Suonsyrja T. Vitamin C for preventing atrial fibrillation in high risk patients: a systematic review and meta-analysis. *BMC Cardiovasc Disord* 2017; 17: 49.

58. Polymeropoulos E, Bagos P, Papadimitriou M, et al. Vitamin C for the Prevention of Postoperative Atrial Fibrillation after Cardiac Surgery: A Meta-Analysis. *Adv Pharm Bull* 2016; 6: 243–250.

59. Carnes CA, Chung MK, Nakayama, T, et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. *Circ Res* 2001; 89: E32–E38.

60. Hu X, Yuan L, Wang H, et al. Efficacy and safety of vitamin C for atrial fibrillation after cardiac surgery: A meta-analysis with trial sequential analysis of randomized controlled trials. *Int J Surg* 2017; 37: 58–64.

61. Cowan JC, Avoiding nitrate tolerance. *Br J Clin Pharmacol* 1992; 34: 96–101.

62. Maxwell SR and Kendall MJ. An update on nitrate tolerance: can it be avoided? *Postgrad Med J* 1992; 68: 857–866.